These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 21184655

  • 1. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
    Shetty N, Derk CT.
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
    [Abstract] [Full Text] [Related]

  • 2. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P, Coghlan G.
    Drugs; 2008 Feb; 68(12):1635-45. PubMed ID: 18681488
    [Abstract] [Full Text] [Related]

  • 3. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
    Steiner MK, Preston IR.
    Vasc Health Risk Manag; 2008 Feb; 4(5):943-52. PubMed ID: 19183742
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Langleben D.
    Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
    [Abstract] [Full Text] [Related]

  • 7. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
    Mucke HA.
    IDrugs; 2009 Jun; 12(6):366-75. PubMed ID: 19517317
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bosentan in systemic sclerosis.
    Heresi GA, Minai OA.
    Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
    [Abstract] [Full Text] [Related]

  • 10. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM.
    Dtsch Med Wochenschr; 2006 Dec 08; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
    Cacoub P, Amoura Z, Langleben D.
    Rev Med Interne; 2008 Apr 08; 29(4):283-9. PubMed ID: 18243424
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.
    Luo N, Ryan JJ.
    Can J Cardiol; 2013 Jun 08; 29(6):659-61. PubMed ID: 22985784
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
    Price LC, Howard LS.
    Am J Cardiovasc Drugs; 2008 Jun 08; 8(3):171-85. PubMed ID: 18533738
    [Abstract] [Full Text] [Related]

  • 18. The endothelin system in pulmonary arterial hypertension.
    Galié N, Manes A, Branzi A.
    Cardiovasc Res; 2004 Feb 01; 61(2):227-37. PubMed ID: 14736539
    [Abstract] [Full Text] [Related]

  • 19. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.
    Varga J.
    Curr Rheumatol Rep; 2003 Apr 01; 5(2):145-6. PubMed ID: 12628045
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.